S&P 500 Industrials Sector SEC Filings — February 11, 2026

12-02-2026

Farmers & Merchants Bancorp Inc filed a Form 8-K on February 12, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, margins, or other financial metrics are disclosed in the provided filing summary. No period-over-period comparisons, guidance, or material impacts are mentioned.

12-02-2026

Coinbase Global, Inc. filed an 8-K on February 12, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results and attaches relevant exhibits, but no specific revenue, earnings, guidance, or other metrics are detailed in the provided information. No positive or negative performance indicators, period-over-period changes, or strategic details are mentioned.

12-02-2026

Sphere Entertainment Co. filed an 8-K on February 12, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or other quantitative financial metrics are disclosed in the provided filing information. No positive or negative performance indicators, period-over-period comparisons, or material events with dollar values are mentioned.

12-02-2026

West Pharmaceutical Services Inc filed an 8-K on February 12, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure of financial results, but specific revenue, earnings, guidance, or period-over-period metrics are NOT_DISCLOSED in the provided information. No positive or negative financial impacts, balance sheet changes, or operational details are available.

12-02-2026

Pilgrim's Pride Corp filed a Form 8-K on February 12, 2026 (AccNo: 0000802481-26-000007), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This is a multi-item filing focused on financial results disclosure. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative metrics are disclosed in the provided filing information.

12-02-2026

Affiliated Managers Group, Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001628280-26-007464), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This multi-item filing pertains to financial results disclosure, likely including a press release or earnings details as exhibits. No specific revenue, earnings, guidance, or other quantitative metrics are explicitly stated in the provided filing information.

12-02-2026

Baxter International Inc. filed an 8-K on February 12, 2026 (AccNo: 0001628280-26-007474), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), alongside results of operations and financial condition (Item 2.02), other events (Item 8.01), and financial statements/exhibits (Item 9.01). Specific details including the officer's name, position, reason for change, timing, financial metrics, or quantitative data are NOT_DISCLOSED. No positive or negative performance metrics, period-over-period comparisons, or scheduled events are mentioned.

• ·Filing size: 1 MB
• ·Source: us_sec
• ·Sector: NOT_DISCLOSED

12-02-2026

Intelligent Bio Solutions Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001493152-26-006317), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific revenue, earnings, balance sheet metrics, period-over-period changes, guidance, or quantitative financial data were disclosed in the provided filing description. This is a multi-item filing focused on financial results disclosure.

12-02-2026

Vertex Pharmaceuticals Inc. / MA filed a Form 8-K on February 12, 2026 (AccNo: 0000875320-26-000034), reporting results of operations and financial condition under Item 2.02 and financial statements and exhibits under Item 9.01. This is a multi-item filing typical for earnings releases, but no specific revenue, earnings, guidance, balance sheet details, or other quantitative metrics were explicitly stated. No positive, negative, or flat performance indicators were disclosed.

12-02-2026

Federal Home Loan Mortgage Corp filed an 8-K on February 12, 2026, under Item 2.02 announcing Results of Operations and Financial Condition, with Financial Statements and Exhibits provided under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics were detailed in the provided filing information. This is a standard voluntary disclosure for financial results.

11-02-2026

Newmarket Corp filed an 8-K on February 11, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing details. This is an informational earnings-related disclosure with no quantitative metrics available.

12-02-2026

InMed Pharmaceuticals Inc. filed an 8-K on February 12, 2026 (AccNo: 0001062993-26-000819, Size: 396 KB), reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure likely including material non-public information and attached exhibits. No financial metrics, transactions, period-over-period changes, or quantitative data are explicitly stated in the filing summary.

11-02-2026

HomeTrust Bancshares, Inc. filed an 8-K on February 11, 2026, reporting under Item 5.02 regarding departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on individuals involved, effective dates, or compensatory terms are disclosed. No financial metrics, quantitative impacts, or other changes are mentioned.

11-02-2026

Enzon Pharmaceuticals, Inc. filed an 8-K on February 11, 2026, reporting Item 5.07 (Submission of Matters to a Vote of Security Holders), indicating results from a shareholder meeting, and Item 9.01 (Financial Statements and Exhibits), which attaches relevant documents. No specific details on proposals voted upon, vote outcomes, or exhibit contents are disclosed. This is a multi-item, mandatory filing with no quantitative financial metrics, changes, or directional impacts provided.

11-02-2026

Biogen Inc. filed a Form 8-K on 2026-02-11 disclosing an unspecified officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers) and other events under Item 8.01. No specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are disclosed. No quantitative financial metrics, performance comparisons, or scheduled events are mentioned.

11-02-2026

Auburn National Bancorporation, Inc. filed a Form 8-K on February 11, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The filing is a multi-item disclosure, likely voluntary for Item 8.01, with no specific details on the events, transactions, financial impacts, or exhibits provided in the available information. No quantitative metrics, positive or negative changes, or material events are disclosed.

11-02-2026

Granite Point Mortgage Trust Inc. filed an 8-K on February 11, 2026, disclosing Results of Operations and Financial Condition under Item 2.02. Financial Statements and Exhibits are provided under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or period-over-period metrics are disclosed.

11-02-2026

MARZETTI CO filed an 8-K on February 11, 2026, disclosing changes related to departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements under Item 5.02. Other events are reported under Item 8.01, with financial statements and exhibits under Item 9.01. No specific details on positions affected, individuals involved, reasons for changes, or any quantitative metrics are disclosed.

11-02-2026

MID PENN BANCORP INC filed an 8-K on February 11, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other event, transaction values, financial impacts, or exhibits are provided in the filing summary. No quantitative metrics, positive or negative changes, or strategic implications are mentioned.

11-02-2026

Watts Water Technologies Inc filed an 8-K on February 11, 2026 (AccNo: 0001104659-26-013437), reporting under Item 2.02 for Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This is a standard disclosure for financial results with attached exhibits, likely including an earnings press release. No specific revenue, earnings, margins, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information.

• ·File size: 1 MB
• ·Event Type: Financial Results
• ·Sector: not specified

11-02-2026

WesBanco Inc filed a Form 8-K on February 11, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary filing likely including attached materials such as a press release or presentation given the 27 MB file size. No specific financial metrics, transactions, guidance, or events are disclosed in the provided filing information.

11-02-2026

Cipher Mining Inc. filed an 8-K on February 11, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), with no specific details on position, individual, or reasons provided. The filing also includes Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). No quantitative metrics, performance comparisons, or further context on the change's implications are disclosed.

11-02-2026

Getty Realty Corp filed an 8-K on February 11, 2026, reporting under Item 7.01 Regulation FD Disclosure, which furnishes material nonpublic information voluntarily, and Item 9.01 Financial Statements and Exhibits, likely attaching related documents such as a press release or presentation (file size 22 MB). No specific financial metrics, transactions, guidance, or quantitative impacts are disclosed in the filing summary. This is a multi-item voluntary disclosure with no mentioned positive or negative performance metrics.

11-02-2026

Leggett & Platt Inc filed an 8-K on February 11, 2026 (AccNo: 0001193125-26-046691), reporting under Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing typical for an earnings release. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information.

11-02-2026

Integrated Biopharma Inc filed an 8-K on February 11, 2026, under Item 2.02 disclosing Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing announcing financial results, but no specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance were detailed in the provided filing information. No positive or negative metrics disclosed.

11-02-2026

Customers Bancorp, Inc. filed a Form 8-K on February 11, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other events, transaction values, financial metrics, or exhibit contents are disclosed in the filing summary. This appears to be a multi-item informational filing with no quantified positive or negative impacts mentioned.

11-02-2026

Elite Pharmaceuticals Inc. /NV/ filed an 8-K on February 11, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific core event, transaction details, financial metrics, or quantitative data are disclosed in the filing summary provided. This is a multi-item informational filing likely including exhibits such as a press release.

11-02-2026

Richmond Mutual Bancorporation, Inc. filed an 8-K on February 11, 2026, under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details regarding the nature of the other events or the contents of the exhibits are disclosed in the provided filing information. This appears to be a voluntary disclosure with attached exhibits.

11-02-2026

BankUnited, Inc. filed an 8-K on February 11, 2026 (AccNo: 0001504008-26-000008, Size: 1 MB) reporting under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific financial metrics, transactions, or performance data disclosed in the provided filing summary. No positive or negative metrics are mentioned.

11-02-2026

Seacoast Banking Corp of Florida filed an 8-K on February 11, 2026, reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific details, financial metrics, transactions, or quantitative data are disclosed in the provided filing summary. This appears to be an informational filing with attached exhibits, but content is NOT_DISCLOSED.

11-02-2026

Glacier Bancorp, Inc. filed an 8-K on February 11, 2026 (AccNo: 0000868671-26-000013, Size: 5 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing indicates a voluntary disclosure of potentially material non-public information with attached exhibits, such as press releases or presentations. No specific financial metrics, transactions, guidance, or events are detailed in the provided filing summary.

11-02-2026

Angel Oak Mortgage REIT, Inc. filed an 8-K on February 11, 2026, specifically under Item 7.01 Regulation FD Disclosure. This is a voluntary disclosure to comply with Regulation FD, but the core content, financial metrics, transactions, or any quantitative data are NOT_DISCLOSED in the provided filing information. No positive, negative, or flat performance metrics are mentioned.

11-02-2026

National Bank Holdings Corp filed a Form 8-K on February 11, 2026, reporting entry into a material definitive agreement under Item 1.01 and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03, along with Regulation FD disclosure in Item 7.01 and exhibits in Item 9.01. No quantitative details such as transaction values, financial terms, or impacts on revenue, earnings, balance sheet, or guidance are disclosed. This multi-item filing signals significant contractual and financing activity but provides no metrics for positive or negative assessment.

11-02-2026

Balance Labs, Inc. filed an 8-K on February 11, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). Item 9.01 indicates financial statements and exhibits were included, but specific details on the affected position, appointment or resignation, reasons, or individuals involved are NOT_DISCLOSED. No quantitative metrics, performance comparisons, or additional corporate actions were mentioned.

11-02-2026

Teradata Corp filed an 8-K on February 11, 2026 (AccNo: 0001628280-26-007274), disclosing under Item 1.01 entry into a material definitive agreement. Item 9.01 provides for financial statements and exhibits. No specific transaction details, financial metrics, dollar values, or impacts are disclosed in the provided filing summary.

11-02-2026

INDEPENDENT BANK CORP filed an 8-K on February 11, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the filing summary provided. Critical details from the exhibits or disclosure content are missing.

11-02-2026

Local Bounti Corporation/DE filed a Form 8-K on 2026-02-11 under Items 3.01, 7.01, and 9.01, disclosing a notice of delisting or failure to satisfy a continued listing rule or standard, along with Regulation FD disclosure and financial statements/exhibits. This event signals non-compliance with exchange listing requirements, potentially leading to transfer to over-the-counter trading. No quantitative financial metrics, positive developments, or period-over-period comparisons were disclosed.

• ·AccNo: 0001628280-26-007269
• ·Filing size: 194 KB
• ·Multi-item 8-K filing (Items 3.01, 7.01, 9.01)

11-02-2026

Phoenix Motor Inc. filed an 8-K on February 11, 2026 (AccNo: 0001493152-26-006203), reporting under Item 3.03 for material modifications to rights of security holders, Item 5.03 for amendments to articles of incorporation or bylaws or change in fiscal year, and Item 9.01 for financial statements and exhibits. This is a multi-item mandatory disclosure with no quantitative financial metrics, transaction values, or performance comparisons disclosed. Specific details on the nature, scope, or impact of the modifications or amendments are not provided.

11-02-2026

Bleichroeder Acquisition Corp. II filed an 8-K on 2026-02-11 (AccNo: 0001213900-26-014891) under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No quantitative metrics, financial data, personnel names, dates, or merger/acquisition details are explicitly stated in the filing summary provided. Sector is not specified, and no positive or negative performance indicators are mentioned.

11-02-2026

M&T Bank Corp filed an 8-K on February 11, 2026 (AccNo: 0000036270-26-000007, size 3 MB), reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary disclosure, likely attaching materials such as a press release or presentation, but specific content, financial metrics, transactions, or events are NOT_DISCLOSED. No positive or negative metrics are provided.

11-02-2026

Gladstone Investment Corporation filed an 8-K on February 11, 2026, reporting under Item 1.01 its entry into a material definitive agreement. Item 9.01 discloses financial statements and exhibits. No specific details regarding the agreement's parties, terms, value, financial impacts, or any quantitative metrics are provided.

11-02-2026

QuidelOrtho Corp filed an 8-K on February 11, 2026 (AccNo: 0001906324-26-000003), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). No specific financial metrics, revenue, earnings, guidance, period-over-period comparisons, or other quantitative details are disclosed in the filing summary. This appears to be a standard earnings-related disclosure with exhibits likely including press releases or financial tables.

11-02-2026

Vanda Pharmaceuticals Inc. filed a Form 8-K on February 11, 2026, under Item 2.02 disclosing results of operations and financial condition and Item 9.01 providing financial statements and exhibits. This is a standard earnings-related disclosure typical for quarterly financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing summary.

11-02-2026

Gouverneur Bancorp, Inc./MD/ filed an 8-K on February 11, 2026, disclosing Item 5.07: Submission of Matters to a Vote of Security Holders. No specific details on the matters voted upon, vote results, attendance, or outcomes are provided in the filing summary. This is purely informational with no financial metrics, changes, or directional implications disclosed.

11-02-2026

Independence Realty Trust, Inc. filed a multi-item Form 8-K on February 11, 2026, reporting entry into a material definitive agreement (Item 1.01) and termination of a material definitive agreement (Item 1.02), alongside results of operations and financial condition (Item 2.02) and creation of a direct financial obligation (Item 2.03). Regulation FD disclosure (Item 7.01) was also included with financial statements and exhibits (Item 9.01). No specific transaction details, financial metrics, dollar values, or performance comparisons are disclosed.

11-02-2026

Amerant Bancorp Inc. filed an 8-K on February 11, 2026, under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. No specific core event, financial metrics, transactions, or directional impacts are detailed in the provided filing information. All quantitative data, guidance, and operational details are NOT_DISCLOSED.

12-02-2026

Artificial Intelligence Technology Solutions Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001062993-26-000822, Size: 587 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing with no specific details on the core event, transaction values, financial metrics, or performance comparisons disclosed in the provided information. No quantitative data, period-over-period changes, positive or negative metrics, or strategic implications are available.

12-02-2026

NovaBay Pharmaceuticals, Inc. filed a Form 8-K on February 12, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details on the other events, financial impacts, transactions, or exhibits are disclosed in the provided filing information. The filing appears informational without quantified metrics or directional implications.

12-02-2026

Applied Materials Inc./DE filed a Form 8-K on February 12, 2026 (AccNo: 0001628280-26-007444, Size: 208 KB), reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details on the core event, disclosures, financial statements, or exhibits are provided. This is a multi-item filing with no quantitative metrics, positive or negative, disclosed.

12-02-2026

Bally's Corp filed an 8-K on February 12, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the other events or content of the exhibits are disclosed in the filing summary. No financial metrics, transactions, or directional impacts are mentioned.

12-02-2026

GEO Group Inc filed an 8-K on February 12, 2026 (AccNo: 0001193125-26-047556), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing announcing financial results, but specific revenue, earnings, guidance, or other metrics are NOT_DISCLOSED. No positive or negative performance details, period-over-period comparisons, or balance sheet impacts are provided in the filing summary.

12-02-2026

Agios Pharmaceuticals, Inc. filed an 8-K on February 12, 2026, disclosing Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, period-over-period comparisons, guidance, or other quantitative financial metrics were detailed in the provided filing information. This appears to be a standard earnings-related disclosure without extracted numerical impacts.

• ·Filing Accession Number: 0001439222-26-000023
• ·Filing size: 371 KB

12-02-2026

Hyatt Hotels Corp filed an 8-K on 2026-02-12 under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing metadata. This is a multi-item voluntary earnings-related disclosure.

12-02-2026

Howmet Aerospace Inc. filed an 8-K on February 12, 2026 (AccNo: 0001104659-26-013832), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing announcing financial results, but specific revenue, earnings, margins, guidance, or period-over-period comparisons are NOT_DISCLOSED. No quantitative metrics, strategic details, or performance directions (positive, negative, or flat) were explicitly stated.

12-02-2026

ConnectOne Bancorp, Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001437749-26-003852, size: 4 MB), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). No specific details regarding the nature of the other events or the content of any financial statements/exhibits are disclosed. This appears to be a multi-item voluntary disclosure with attached materials.

12-02-2026

Iridium Communications Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001418819-26-000008), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This constitutes a multi-item filing disclosing financial results with attached exhibits. No specific revenue, earnings, margins, or period-over-period metrics are detailed in the provided filing information.

12-02-2026

ADVANCED DRAINAGE SYSTEMS, INC. filed an 8-K on February 12, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, or operational details are disclosed in the filing summary. The disclosure appears informational with no mentioned positive or negative impacts.

12-02-2026

PHINIA INC. filed an 8-K on February 12, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure with no detailed performance data available.

12-02-2026

Karyopharm Therapeutics Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001193125-26-047670), reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing typical for earnings announcements, but no specific revenue, earnings, balance sheet details, period-over-period comparisons, or other quantitative metrics are disclosed in the provided summary. No positive or negative financial changes can be assessed due to lack of data.

• ·Filing size: 550 KB
• ·Source: us_sec
• ·Sector: NOT_DISCLOSED

12-02-2026

Optimum Communications, Inc. filed an 8-K on February 12, 2026, reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing announcing financial results, but no specific revenue, earnings, guidance, or other quantitative metrics are disclosed in the provided filing information. No positive or negative performance indicators, period-over-period comparisons, or balance sheet details are available.

12-02-2026

Avadel Pharmaceuticals PLC filed an 8-K on 2026-02-12 disclosing the completion of an acquisition or disposition of assets under Item 2.01, changes in control of the registrant under Item 5.01, and notice of delisting or failure to satisfy listing standards under Item 3.01. The filing also reports termination of a material definitive agreement (Item 1.02), material modifications to rights of security holders (Item 3.03), departures or elections of directors/officers and compensatory arrangements (Item 5.02), and amendments to articles of incorporation or bylaws or change in fiscal year (Item 5.03), along with Regulation FD disclosure (Item 7.01) and financial statements/exhibits (Item 9.01). No quantitative financial metrics, deal values, parties, or specific terms were disclosed.

12-02-2026

Belden Inc. filed an 8-K on February 12, 2026, under Item 2.02 announcing Results of Operations and Financial Condition, accompanied by Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the filing summary provided. This appears to be a standard earnings-related disclosure with no detailed performance data available.

12-02-2026

Alnylam Pharmaceuticals, Inc. filed an 8-K on February 12, 2026 (AccNo: 0001628280-26-007491), disclosing results of operations and financial condition under Item 2.02 and providing financial statements and exhibits under Item 9.01. This is a multi-item filing focused on financial results announcement. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative metrics are disclosed in the provided filing information.

12-02-2026

IPG Photonics Corp filed an 8-K on 2026-02-12 reporting Results of Operations and Financial Condition under Item 2.02, accompanied by Financial Statements and Exhibits under Item 9.01. This is a multi-item filing typical for earnings releases. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing details.

12-02-2026

Voyager Therapeutics, Inc. filed an 8-K on 2026-02-12 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) and other events under Item 8.01. No specific details on the key position affected, appointment or resignation, reasons, timing, or any quantitative data such as compensation amounts or share counts are disclosed. Sector is not specified.

12-02-2026

Cue Biopharma, Inc. filed an 8-K on February 12, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, effective dates, or any financial metrics are provided in the filing summary. This represents a standard governance disclosure with no quantified positive or negative impacts mentioned.

12-02-2026

Euronet Worldwide, Inc. filed a Form 8-K on February 12, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), announcing financial results. No specific revenue, earnings, margins, period-over-period changes, or other quantitative metrics were disclosed in the provided filing information. This appears to be a standard voluntary earnings release attachment.

12-02-2026

12-02-2026

Benitec Biopharma Inc. filed an 8-K on February 12, 2026 (AccNo: 0001193125-26-047742), reporting under Item 2.02 Results of Operations and Financial Condition, with exhibits under Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, balance sheet changes, guidance, or quantitative financial metrics are disclosed in the provided filing information. No positive or negative performance indicators, period-over-period comparisons, or transaction details are mentioned.

12-02-2026

Diodes Inc. filed an 8-K on February 12, 2026 (AccNo: 0001193125-26-048964), disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. This is a multi-item filing related to financial results, but no specific revenue, earnings, guidance, or other quantitative metrics are mentioned. No positive or negative performance details, period-over-period comparisons, or forward-looking statements are provided in the filing information.

12-02-2026

Ballston Spa Bancorp, Inc. filed an 8-K on February 12, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the events, transactions, financial metrics, or exhibits are disclosed in the provided filing information.

12-02-2026

GENESIS ENERGY LP filed an 8-K on February 12, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, guidance, or period-over-period comparisons are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed quantitative data.

12-02-2026

60 Degrees Pharmaceuticals, Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001213900-26-015239, Size: 238 KB), reporting solely under Item 8.01 Other Events. No details on the nature of the other event, financial metrics, transactions, or quantitative data are disclosed in the provided filing information. Sector not specified.

12-02-2026

Sonoco Products Co filed an 8-K on February 12, 2026 (AccNo: 0001104659-26-013958, Size: 226 KB), disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the affected officers, positions, reasons for change, appointments, resignations, or any quantitative financial metrics are disclosed. The event is informational with no mentioned positive or negative performance indicators.

12-02-2026

Under Armour, Inc. filed an 8-K on February 12, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 indicates financial statements and exhibits were included. No specific details on the officer, position affected, reason for change, or any quantitative metrics are disclosed.

12-02-2026

Totaligent, Inc. filed an 8-K on February 12, 2026, reporting under Item 1.01 entry into a Material Definitive Agreement and under Item 9.01 Financial Statements and Exhibits. No details on the agreement's terms, parties, value, strategic importance, or financial impact were disclosed. This is a multi-item mandatory filing with no quantitative metrics or period-over-period comparisons provided.

12-02-2026

ADDENTAX GROUP CORP. filed a Form 8-K on February 12, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the exhibits are disclosed in the filing summary. File size is 229 KB with Accession Number 0001493152-26-006327.

12-02-2026

SAGA COMMUNICATIONS INC filed a Form 8-K on February 12, 2026, disclosing Other Events under Item 8.01 and Financial Statements and Exhibits under Item 9.01. No specific details regarding the nature of the other events or the contents of the exhibits are provided. All quantitative data, transaction details, and financial impacts are NOT_DISCLOSED.

12-02-2026

Aspire Biopharma Holdings, Inc. filed a multi-item Form 8-K on February 12, 2026, disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), departures or appointments of directors/officers or compensatory arrangements (Item 5.02), Regulation FD disclosure (Item 7.01), and financial statements/exhibits (Item 9.01). No specific details, transaction values, financial impacts, or quantitative metrics are disclosed in the provided filing summary. No positive or negative metrics are mentioned.

12-02-2026

Magyar Bancorp, Inc. filed an 8-K on February 12, 2026, reporting under Item 5.07 the submission of matters to a vote of security holders, likely related to a shareholder meeting, and under Item 9.01 financial statements and exhibits. No specific vote outcomes, financial metrics, positive or negative changes, or other quantitative details are disclosed.

12-02-2026

Fresh Del Monte Produce Inc filed an 8-K on 2026-02-12 disclosing entry into a material definitive agreement under Item 1.01. The filing also includes financial statements and exhibits under Item 9.01. No details on the agreement terms, parties, financial impact, or quantitative metrics are provided.

12-02-2026

FVCBankcorp, Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001675644-26-000006, size: 25 MB), reporting multiple items including entry into a material definitive agreement (Item 1.01), creation of a direct financial obligation or off-balance sheet arrangement (Item 2.03), Regulation FD disclosure (Item 7.01), other events (Item 8.01), and financial statements/exhibits (Item 9.01). No quantitative metrics, transaction details, financial impacts, period-over-period comparisons, or specific terms are disclosed.

• ·Multi-item 8-K filing (5 items reported)
• ·File size: 25 MB (suggests detailed exhibits)

12-02-2026

FIRST US BANCSHARES, INC. filed an 8-K on February 12, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for change, timing, or any quantitative metrics are disclosed.

12-02-2026

Kentucky First Federal Bancorp filed a Form 8-K on February 12, 2026 (AccNo: 0001213900-26-015539), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. This represents a standard voluntary earnings-related disclosure with no specific revenue, earnings, balance sheet changes, or period-over-period comparisons detailed in the provided filing information. No positive or negative financial metrics were quantified.

12-02-2026

Phillips Edison & Company, Inc. filed an 8-K on February 12, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, events, or quantitative data are detailed in the filing summary provided. Critical details of the disclosure are missing, limiting assessment of impact.

12-02-2026

Seaboard Corp /DE/ filed a Form 8-K on February 12, 2026, reporting Results of Operations and Financial Condition under Item 2.02. Item 9.01 includes Financial Statements and Exhibits. No specific revenue, earnings, balance sheet metrics, period-over-period changes, or guidance are disclosed in the provided filing information.

• ·AccNo: 0000088121-26-000010
• ·File Size: 223 KB
• ·Sector: sector not specified

12-02-2026

Quaint Oak Bancorp, Inc. filed an 8-K on February 12, 2026, reporting under Item 5.03 amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 discloses financial statements and exhibits. No specific details, financial metrics, dollar values, or impacts are provided.

12-02-2026

BridgeBio Pharma, Inc. filed an 8-K on February 12, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the nature of the other events or exhibits provided in the summary. No financial metrics, transactions, or performance data are disclosed.

12-02-2026

MASCO CORP /DE/ filed an 8-K on 2026-02-12 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for changes, or any quantitative metrics are provided in the filing summary. No positive or negative performance metrics, financial impacts, or further context are mentioned.

12-02-2026

SOLIGENIX, INC. filed a Form 8-K on February 12, 2026 (AccNo: 0001104659-26-014267, Size: 226 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details on the nature of the other events or the financial statements/exhibits are disclosed. No quantitative metrics, positive or negative changes, or performance comparisons provided.

12-02-2026

Dexcom Inc filed a Form 8-K on February 12, 2026 (AccNo: 0001093557-26-000025, Size: 692 KB), disclosing Results of Operations and Financial Condition under Item 2.02 and Financial Statements and Exhibits under Item 9.01. This multi-item filing represents a standard voluntary earnings-related disclosure. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics were detailed in the provided filing information.

12-02-2026

Edgemode, Inc. filed an 8-K on February 12, 2026, under Item 5.02 disclosing a change involving departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on affected positions, individuals, reasons, timing, or any quantitative metrics are provided.

12-02-2026

Rivian Automotive, Inc. filed a Form 8-K on February 12, 2026, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits), indicating a voluntary disclosure of financial results typically accompanying an earnings release. This is a multi-item filing with no specific revenue, earnings, balance sheet effects, guidance, or other quantitative metrics explicitly stated in the provided information. No positive, negative, or flat performance indicators are disclosed.

12-02-2026

Supernus Pharmaceuticals, Inc. filed an 8-K on February 12, 2026, under Item 2.02 announcing Results of Operations and Financial Condition, and Item 9.01 providing Financial Statements and Exhibits. No specific revenue, earnings, or other quantitative financial metrics are disclosed in the filing description. This appears to be a standard earnings-related disclosure with attached exhibits, but detailed performance data is not available.

12-02-2026

Pro-Dex Inc filed an 8-K on February 12, 2026, disclosing entry into a material definitive agreement under Item 1.01, completion of an acquisition or disposition of assets under Item 2.01, and creation of a direct financial obligation or off-balance sheet arrangement under Item 2.03. Regulation FD disclosure was provided under Item 7.01, with financial statements and exhibits attached under Item 9.01. No specific transaction details, parties, values, or metrics are disclosed in the provided filing summary.

12-02-2026

Public Storage filed an 8-K on February 12, 2026, under Item 5.02 disclosing departure of directors or certain officers, election or appointment of directors/officers, or compensatory arrangements; Item 7.01 for Regulation FD disclosure; Item 8.01 for other events; and Item 9.01 for financial statements and exhibits. No specific details on the officer affected, position, appointment/resignation status, reasons, or any financial metrics are disclosed. This filing provides limited transparency on the leadership change event.

12-02-2026

10x Genomics, Inc. filed an 8-K on February 12, 2026 (AccNo: 0001628280-26-007673), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific financial metrics, period-over-period comparisons, guidance, or other quantitative details are disclosed in the provided filing information.

12-02-2026

VenHub Global, Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001213900-26-015576), reporting under Item 1.01 entry into a material definitive agreement, Item 3.02 unregistered sales of equity securities, Item 8.01 other events, and Item 9.01 financial statements and exhibits. This is a multi-item filing with no specific transaction values, financial metrics, or performance comparisons disclosed. No positive or negative metrics are provided.

12-02-2026

Catheter Precision, Inc. filed a multi-item 8-K on February 12, 2026, disclosing entry into a material definitive agreement (Item 1.01), unregistered sales of equity securities (Item 3.02), amendments to articles of incorporation or bylaws (Item 5.03), and Regulation FD disclosure (Item 7.01). While the material agreement may signal strategic progress, the unregistered equity sales raise potential dilution concerns and the governance changes introduce uncertainty without specified details. No quantitative transaction values, share counts, financial impacts, or period-over-period comparisons are disclosed.

12-02-2026

Anebulo Pharmaceuticals, Inc. filed an 8-K on February 12, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific financial metrics, revenue, earnings, balance sheet details, or period-over-period comparisons were disclosed in the filing summary provided. This appears to be a standard earnings-related disclosure without quantified data.

12-02-2026

Bain Capital GSS Investment Corp. filed an 8-K on February 12, 2026, disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates Financial Statements and Exhibits were included. No specific details on the affected position, individual names, appointment or resignation status, reasons, or timing are disclosed.

12-02-2026

Sphere 3D Corp. filed a Form 8-K on February 12, 2026, reporting under Item 3.03 material modifications to the rights of security holders and under Item 5.03 amendments to its articles of incorporation or bylaws or a change in fiscal year. The filing also includes Item 7.01 for Regulation FD disclosure and Item 9.01 for financial statements and exhibits. No quantitative financial metrics, transaction values, or specific details on the modifications, impacts, or exhibits were disclosed in the provided information.

12-02-2026

loanDepot, Inc. filed an 8-K on February 12, 2026 (AccNo: 0001831631-26-000004), disclosing entry into a Credit Agreement under Item 8.01 Other Events. No specific dollar values, terms, financial impacts, or other metrics were mentioned in the filing details provided. This represents a voluntary disclosure of a financing-related event.

12-02-2026

BioMarin Pharmaceutical Inc filed an 8-K on February 12, 2026, reporting under Item 1.01 entry into a material definitive agreement, Item 2.03 creation of a direct financial obligation or off-balance sheet arrangement, Item 7.01 Regulation FD disclosure, and Item 9.01 financial statements and exhibits. This is a multi-item mandatory filing for material events, but specific details on the agreement, transaction size, parties, or financial impacts are NOT_DISCLOSED. No quantitative metrics, period-over-period comparisons, or scheduled events are mentioned.

12-02-2026

Ultragenyx Pharmaceutical Inc. filed a Form 8-K on February 12, 2026 (AccNo: 0001193125-26-048738), reporting results of operations and financial condition under Item 2.02 alongside costs associated with exit or disposal activities under Item 2.05, with financial statements and exhibits under Item 9.01. This multi-item filing provides an update on financial performance but highlights potential negative impacts from exit-related costs. No specific revenue, earnings, cost amounts, or period-over-period comparisons are disclosed.

12-02-2026

Grand Canyon Education, Inc. filed an 8-K on 2026-02-12 under Item 5.02 disclosing departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals, reasons for change, or impacts are provided. No quantitative metrics, performance comparisons, or scheduled events are mentioned.

12-02-2026

Murphy USA Inc. filed an 8-K on February 12, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This multi-item filing is primarily voluntary, aimed at publicly disclosing material non-public information via attached exhibits. No quantitative metrics, transactions, period-over-period comparisons, financial impacts, or scheduled events are explicitly stated in the filing summary.

12-02-2026

Vistagen Therapeutics, Inc. filed an 8-K on February 12, 2026 (AccNo: 0001628280-26-007715), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance are disclosed in the provided filing information. This is a standard multi-item disclosure for financial results.

12-02-2026

12-02-2026

Great Lakes Dredge & Dock CORP filed a Form 8-K on February 12, 2026 (AccNo: 0001171843-26-000790), reporting solely under Item 8.01 Other Events. No details on the specific event, transaction, financial metrics, or impacts are disclosed in the provided filing information. This appears to be a single-item, likely voluntary disclosure of an unspecified material event.

12-02-2026

Ingersoll Rand Inc. filed an 8-K on February 12, 2026 (AccNo: 0001628280-26-007710), reporting under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific revenue, earnings, guidance, balance sheet impacts, or other quantitative financial metrics are disclosed in the provided filing information. No period-over-period comparisons, positive or negative changes, or operational details are available.

12-02-2026

Farmers & Merchants Bancorp filed an 8-K on February 12, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. Specific details of the other event, any financial statements, or exhibits are NOT_DISCLOSED in the provided filing summary. No quantitative metrics, comparisons, or directional changes are mentioned.

12-02-2026

Middlefield Banc Corp filed an 8-K on February 12, 2026, under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, names of individuals, reasons for the change, or any quantitative data such as compensation amounts are disclosed. Sector information is not specified.

12-02-2026

Bain Capital Specialty Finance, Inc. filed an 8-K on February 12, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific financial metrics, quantitative data, period-over-period comparisons, or guidance were mentioned in the filing details provided. This appears to be a standard earnings-related disclosure without detailed performance indicators.

12-02-2026

Republic Services, Inc. filed an 8-K on 2026-02-12 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers), with no specific details on the officer, position, or reason provided. The filing also covers Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits), filed under AccNo: 0001060391-26-000066 (size: 540 KB). No quantitative metrics, financial impacts, or performance comparisons are mentioned.

• ·Filing AccNo: 0001060391-26-000066
• ·File Size: 540 KB
• ·Event Date: 2026-02-12
• ·Sector: NOT_DISCLOSED

12-02-2026

Corebridge Financial, Inc. filed a Form 8-K on 2026-02-12 disclosing under Item 1.01 entry into a material definitive agreement. Item 9.01 references financial statements and exhibits. No specific details, transaction values, financial metrics, positive or negative impacts, or comparisons are disclosed.

12-02-2026

SafeSpace Global Corp filed a Form 8-K on February 12, 2026, specifically under Item 7.01 Regulation FD Disclosure. This single-item voluntary filing discloses material non-public information previously shared selectively, but no financial metrics, transactions, or other quantitative details are provided. No positive or negative performance indicators are mentioned.